Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexarotene oral - Eisai Co Ltd

Drug Profile

Bexarotene oral - Eisai Co Ltd

Alternative Names: BSC-1; LGD 1069; LGD 1069 oral; Targretin; Targretin capsules; Targretin oral; Targretyn oral; Targretyn™; Targrexin oral

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Eisai Co Ltd; Minophagen
  • Class Antineoplastics; Antipsoriatics; Benzoic acids; Naphthalenes; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma
  • Phase II Adult T-cell leukaemia-lymphoma
  • Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Psoriasis; Renal cell carcinoma; Thyroid cancer

Most Recent Events

  • 22 Dec 2021 Minophagen Pharmaceutical completes enrollment in a phase-II trial in Adult T-cell leukaemia-lymphoma in Japan (PO) (JapicCTI-184233)
  • 03 Nov 2020 Launched for Cutaneous T-cell lymphoma in Argentina (PO)
  • 28 Sep 2020 Launched for Cutaneous T-cell lymphoma in Greece (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top